Table 1

Baseline characteristics of the included studies

Eslami et al11 2020Abbaspour Kasgari et al12 2020Roozbeh et al16 2021Sadeghi et al9 2020
Study designOpen-label parallelRCTRCTRCT
Trial registration numberIRCT20200324046850N2IRCT20200328046886N1IRCT20200403046926N1IRCT20200128046294N2
Country of originIranIranIranIran
SettingInpatientsInpatientsOutpatientsInpatients
COVID-19 severitySevereModerateUnclearModerate/severe
Sample size35 vs 2724 vs 2427 vs 2833 vs 33
Intervention400 mg SOF and 60 mg DCV400 mg SOF and 60 mg DCV+600 mg ribavirin400 mg SOF and 60 mg DCV+HCQ400 mg SOF and 60 mg DCV+SOC
Control600 mg ribavirin600 mg ribavirin+HCQ+400 mg iopinavir and 100 mg ritonavir two times per dayHCQSOC
Age (years)61534560
Male (%)513747.351.5
Diabetes (%)27.429.242.4
COPD (%)9.62.1
CKD (%)3.8
CVD (%)23.123
Haemoglobin (g/L)120120120
WBC (×109/L)7.66.38.5
Lymphocyte (×109/L)1.21.3
AST (IU/L)302635
ALT (IU/L)232232
Creatinine (mg/dL)1.10.91
Risk of biasNOS: 7 out of 9Low–moderateLow–moderateLow–moderate
FundingAbadan Faculty of Medical SciencesMazandaran University of Medical SciencesVice-Chancellor for Research at
Mazandaran University of Medical Sciences
Digestive Disease
Research Institute of Tehran University of Medical Science
  • ALT, alanine aminotransferase; AST, aspartate aminotransferase; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DCV, daclatasvir; HCQ, hydroxychloroquine; NOS, Newcastle-Ottawa Scale; RCT, randomised controlled trial; SOC, standard of care; SOF, sofosbuvir; WBC, white blood cells.